Genesee Capital Advisors LLC Grows Position in Hims & Hers Health, Inc. $HIMS

Genesee Capital Advisors LLC raised its position in Hims & Hers Health, Inc. (NYSE:HIMSFree Report) by 8.7% in the second quarter, Holdings Channel.com reports. The institutional investor owned 37,699 shares of the company’s stock after purchasing an additional 3,013 shares during the period. Hims & Hers Health comprises approximately 0.8% of Genesee Capital Advisors LLC’s holdings, making the stock its 28th largest position. Genesee Capital Advisors LLC’s holdings in Hims & Hers Health were worth $1,879,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. Northern Trust Corp raised its position in Hims & Hers Health by 19.5% in the 1st quarter. Northern Trust Corp now owns 2,435,512 shares of the company’s stock valued at $71,969,000 after purchasing an additional 397,310 shares during the last quarter. Yong Rong HK Asset Management Ltd raised its holdings in shares of Hims & Hers Health by 41.2% in the first quarter. Yong Rong HK Asset Management Ltd now owns 2,400,000 shares of the company’s stock valued at $70,920,000 after buying an additional 700,100 shares during the last quarter. Nuveen LLC acquired a new stake in shares of Hims & Hers Health during the first quarter worth about $58,403,000. BIT Capital GmbH boosted its stake in shares of Hims & Hers Health by 7.4% during the first quarter. BIT Capital GmbH now owns 1,642,493 shares of the company’s stock worth $48,536,000 after buying an additional 112,949 shares during the period. Finally, Bank of New York Mellon Corp grew its holdings in shares of Hims & Hers Health by 1.2% during the first quarter. Bank of New York Mellon Corp now owns 1,260,292 shares of the company’s stock worth $37,242,000 after buying an additional 15,339 shares during the last quarter. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Hims & Hers Health Stock Down 7.3%

Hims & Hers Health stock opened at $53.98 on Monday. The stock’s 50 day moving average price is $50.86 and its 200 day moving average price is $48.11. Hims & Hers Health, Inc. has a 1-year low of $17.36 and a 1-year high of $72.98. The company has a market cap of $12.20 billion, a PE ratio of 67.48, a price-to-earnings-growth ratio of 3.65 and a beta of 2.25. The company has a debt-to-equity ratio of 1.72, a current ratio of 4.98 and a quick ratio of 4.46.

Hims & Hers Health (NYSE:HIMSGet Free Report) last released its earnings results on Monday, August 4th. The company reported $0.17 EPS for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). The business had revenue of $544.83 million during the quarter, compared to analyst estimates of $550.06 million. Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. Hims & Hers Health’s revenue was up 72.6% compared to the same quarter last year. During the same period last year, the business posted $0.06 EPS. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, sell-side analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

HIMS has been the subject of several analyst reports. Wall Street Zen downgraded Hims & Hers Health from a “buy” rating to a “hold” rating in a research note on Monday, July 28th. Weiss Ratings restated a “hold (c)” rating on shares of Hims & Hers Health in a research note on Saturday, September 27th. Citigroup reaffirmed a “sell” rating on shares of Hims & Hers Health in a report on Monday, June 23rd. UBS Group set a $30.00 price objective on shares of Hims & Hers Health in a research report on Monday, June 23rd. Finally, Zacks Research downgraded shares of Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 19th. Two research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, Hims & Hers Health presently has a consensus rating of “Reduce” and a consensus target price of $38.92.

Read Our Latest Stock Report on HIMS

Insider Activity

In other news, CFO Oluyemi Okupe sold 11,595 shares of the business’s stock in a transaction that occurred on Friday, October 3rd. The stock was sold at an average price of $57.72, for a total transaction of $669,263.40. Following the sale, the chief financial officer owned 70,232 shares of the company’s stock, valued at $4,053,791.04. The trade was a 14.17% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Irene Becklund sold 8,410 shares of the company’s stock in a transaction that occurred on Wednesday, September 17th. The stock was sold at an average price of $50.50, for a total value of $424,705.00. Following the completion of the sale, the insider owned 1,418 shares in the company, valued at approximately $71,609. This represents a 85.57% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,608,588 shares of company stock valued at $83,020,063 in the last quarter. Insiders own 17.71% of the company’s stock.

About Hims & Hers Health

(Free Report)

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Recommended Stories

Want to see what other hedge funds are holding HIMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hims & Hers Health, Inc. (NYSE:HIMSFree Report).

Institutional Ownership by Quarter for Hims & Hers Health (NYSE:HIMS)

Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.